A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System
← catalyst calendarNCT07194265 · readout ≤ 499 d
Sponsored by Anteris Technologies Ltd. (industry) · AVR — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
1,650estimated
Sites
1
Country
Denmark
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-21 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2038 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Severe Aortic Stenosis
- Valve-in-valve Procedures
Interventions
- Device: TAVR with DurAVR® THV
- Device: TAVR with SAPIEN THV series or the Evolut THV series
Primary outcome
what the primary-completion date above is the date OFComposite of all-cause mortality, all stroke and cardiovascular hospitalization
measured 1 Year
Permalink · AVR's whole pipeline · Catalyst calendar · Every registered study · What changed